Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
2022年 希少疾病用医薬品動向 Evaluate オーファンドラッグ 2022 レポート 日本語版リリース
東京、日本－2022年5月26日 – 製薬業界における戦略策定や事業性評価に不可欠な信頼性の高いマーケット情報及び分析を提供するEvaluate（エバリュエート本社：ロンドン）は、2022年4月に発行した希少疾病用医薬品動向レポート 「オーファンドラッグ 2022 レポート」（原文：英語）の日本語版をリリースしました。
Evaluate appoints Matthew Wright as Chief Financial Officer
London, UK and Boston, MA – 11 May 2022 – Evaluate, a leading provider of market intelligence and predictive analytics for the pharmaceutical industry, has today…
Four prominent pharmaceutical solutions providers launch Norstella to drive innovation and get patients access to life-saving therapies faster
United under Norstella, each brand’s key solutions and expertise will help life-sciences-focused companies get answers—not just insights—from pipeline to patient
Biopharma Stages A Strong Recovery Over The First Half Even As M&A Deals Disappoint, While Unprecedented Amounts Of Money Flow In Medtech But Not Towards Smaller Innovators
EP Vantage Releases Half-Year Reviews of Pharma & Biotech and Medtech Performance.
Japanese Pharmaceutical Market Set To Grow 3.3% (Cagr) Between 2017 And 2022, Significantly Lower Than The Worldwide Outlook (6.5% Cagr)
Latest growth forecasts show optimism surrounding new therapies coming to market counterbalanced by more stringent pricing policy enforcement.
Epi Analyzer: Blockbusters Out, Highly Targeted Therapies In
New Case Studies Highlight Niche Patient Population Identification and Analysis for Enhanced Portfolio Decision-making Using Evaluate’s Epi Analyzer
Pricing Pressure Causes Worldwide Drug Sales Forecasts To Fall For First Time In 10 Years
Fall comes as average cost of developing new drugs totals $4bn over the last 10 years.
Worldwide Prescription Drug Sales to Top Trillion Dollar Mark in 2022 with 32% of the 2022 Increase in Sales to Come From Orphan Drugs
Annual Pharma & Biotech World Preview Report to Launch at Bio 2017
Median cost per patient for orphan drugs is 5.5 times higher than non-orphan drugs
Annual "EvaluatePharma Orphan Drug 2017 Report" sees continued growth (CAGR 2017 to 2022: +11.1%) for orphan drugs, approximately double overall prescription…
Pharma and Medtech sectors struggle in first half of 2016
Falling stock markets, political uncertainty and continued global economic weakness all contributed to a mixed first half for the pharma and medtech industries.
Evaluate Ltd named in 'Ones to recognise' category in Sunday Times annual BDO Profit Track 100
Life science market intelligence firm, Evaluate Ltd today announces that it has been selected as one of 10 companies in the “Ones to Recognise” category in the Sunday…
Press Releases
Welcome to our press release archive. To learn more about how we work with healthcare and business reporters worldwide, or if you are looking for specific data and expert insights to support a current story, please contact us at media@evaluate.com.
